Skip to main content
Assets
AstraZeneca logo
AZN.LSE
AstraZeneca
Health Care · Pharmaceuticals

British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.

HQ: United KingdomListed: United Kingdom

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for AstraZeneca.

Historical AI Forecasts

AstraZeneca plc (AZN.LSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+62.1%

Includes 0.02% annual net dividend contribution

1. Investment Thesis — Base Case

The central thesis relies on AstraZeneca's proven ability to execute its 'Ambition 2030' strategy. We forecast steady double-digit earnings growth driven by the continued dominance of its oncology portfolio and the successful integration of Alexion's rare disease franchise. While pricing pressures in the U.S. and China will create headwinds, volume growth in new indications and emerging markets will offset these declines. The company is expected to maintain its through sustained R&D productivity. Valuation remains reasonable relative to peers, with the stock likely to track earnings growth and modest as pipeline assets derisk.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.5.31K10.05K14.79K19.53K24.27KNov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (GBX)
Observed price2020-11-257,800
Observed price2020-12-118,160
Observed price2020-12-197,491
Observed price2020-12-237,224
Observed price2021-01-167,625
Observed price2021-01-247,835
Observed price2021-02-097,268
Observed price2021-02-177,394
Observed price2021-03-056,894
Observed price2021-03-217,290
Observed price2021-04-067,111
Observed price2021-04-147,284
Observed price2021-05-087,699
Observed price2021-05-127,786
Observed price2021-05-248,150
Observed price2021-06-098,109
Observed price2021-07-038,765
Observed price2021-07-118,719
Observed price2021-07-318,275
Observed price2021-08-088,232
Observed price2021-08-208,708
Observed price2021-09-178,063
Observed price2021-09-218,710
Observed price2021-10-119,003
Observed price2021-10-198,739
Observed price2021-11-049,443
Observed price2021-11-208,412
Observed price2021-12-108,193
Observed price2021-12-188,480
Observed price2021-12-308,673
Observed price2022-01-078,351
Observed price2022-01-198,785
Observed price2022-02-048,356
Observed price2022-03-048,853
Observed price2022-03-129,302
Observed price2022-03-169,472
Observed price2022-04-0910,824
Observed price2022-04-2510,319
Observed price2022-05-0310,684
Observed price2022-05-1110,026
Observed price2022-05-2310,600
Observed price2022-06-169,760
Observed price2022-07-0210,804
Observed price2022-07-1011,104
Observed price2022-07-2210,766
Observed price2022-08-1110,506
Observed price2022-08-1911,250
Observed price2022-08-3110,773
Observed price2022-09-249,934
Observed price2022-09-2810,076
Observed price2022-10-229,719
Observed price2022-10-2610,034
Observed price2022-11-1910,942
Observed price2022-11-2310,996
Observed price2022-12-0911,354
Observed price2022-12-2111,244
Observed price2023-01-0611,717
Observed price2023-01-1811,510
Observed price2023-02-0310,333
Observed price2023-02-1911,496
Observed price2023-03-1110,695
Observed price2023-03-1510,742
Observed price2023-04-0811,612
Observed price2023-04-1211,773
Observed price2023-04-2412,267
Observed price2023-05-2212,028
Observed price2023-05-3011,498
Observed price2023-06-0711,754
Observed price2023-07-0110,805
Observed price2023-07-0910,096
Observed price2023-07-2910,943
Observed price2023-08-1011,162
Observed price2023-08-1810,658
Observed price2023-09-0310,683
Observed price2023-09-2311,076
Observed price2023-09-2711,085
Observed price2023-10-2110,432
Observed price2023-10-2510,415
Observed price2023-11-1410,169
Observed price2023-11-2610,026
Observed price2023-12-1210,243
Observed price2023-12-2010,413
Observed price2024-01-0910,902
Observed price2024-01-2910,568
Observed price2024-02-109,662
Observed price2024-02-149,724
Observed price2024-03-0910,342
Observed price2024-03-1710,261
Observed price2024-03-2910,696
Observed price2024-04-1010,732
Observed price2024-05-0412,141
Observed price2024-05-2412,329
Observed price2024-05-2812,028
Observed price2024-06-2512,550
Observed price2024-06-2912,316
Observed price2024-07-0712,000
Observed price2024-07-2712,212
Observed price2024-07-3112,368
Observed price2024-08-2013,102
Observed price2024-09-0113,276
Observed price2024-09-2111,716
Observed price2024-09-2911,621
Observed price2024-10-1511,980
Observed price2024-10-2311,780
Observed price2024-11-089,790
Observed price2024-11-2010,043
Observed price2024-12-0210,746
Observed price2024-12-1810,375
Observed price2025-01-1110,905
Observed price2025-01-1510,648
Observed price2025-02-0811,752
Observed price2025-02-2011,590
Observed price2025-03-0412,064
Observed price2025-03-1611,920
Observed price2025-04-0510,724
Observed price2025-04-099,667
Observed price2025-05-0310,645
Observed price2025-05-1510,176
Observed price2025-05-3110,486
Observed price2025-06-1211,030
Observed price2025-06-2810,132
Observed price2025-07-1810,294
Observed price2025-07-2610,848
Observed price2025-08-0710,950
Observed price2025-08-2311,978
Observed price2025-09-0412,150
Observed price2025-09-2011,293
Observed price2025-09-2811,055
Observed price2025-10-1012,886
Observed price2025-10-2212,485
Observed price2025-11-1513,541
Observed price2025-11-2714,061
Observed price2025-12-1313,460
Observed price2025-12-1713,527
Observed price2026-01-1014,148
Observed price2026-01-1414,346
Observed price2026-01-2213,560
Observed price2026-02-2715,542
Observed price2026-03-0714,608
Observed price2026-03-2313,742
Observed price2026-04-0415,283
Observed price2026-04-0815,216
Observed price2026-05-0213,701
Observed price2026-05-0613,322
Observed price2026-05-2213,997
Observed price2026-06-1513,200
Observed price2026-06-2714,180
Observed price2026-07-0514,219
Observed price2026-07-2112,492
Observed price2026-07-2913,134
Observed price2026-08-1411,460
Observed price2026-08-2612,234
Observed price2026-09-1111,708
Observed price2026-09-1612,136
Observed price2026-09-1812,500
Published advisor forecast2025-11-2714,012
Published advisor forecast2026-05-2814,755
Published advisor forecast2026-11-2815,551
Published advisor forecast2027-05-2816,407
Published advisor forecast2027-11-2817,309
Published advisor forecast2028-05-2818,261
Published advisor forecast2028-11-2819,119
Published advisor forecast2029-05-2820,018
Published advisor forecast2029-11-2820,979
Published advisor forecast2030-05-2821,839
Published advisor forecast2030-11-2822,691

2. Scenarios & Signals

Bull case

In this scenario, AstraZeneca significantly outperforms consensus expectations, driven by blockbuster success in its next-generation , particularly with antibody-drug conjugates () like Enhertu and Dato-DXd gaining wider first-line approvals. The company successfully navigates geopolitical tensions in China, realizing high-growth revenue streams from emerging markets without significant regulatory blowback. programs leverage AI in R&D to cut drug discovery costs, expanding above 35%. Global macro conditions favor defensive growth stocks, with interest rate cuts stimulating . Investor sentiment shifts to view AZN not just as a pharma major but as a top-tier growth , driving the P/E ratio significantly higher.

Bear case

The bear case envisions a confluence of regulatory and clinical setbacks. Key late-stage trials in lung and breast cancer fail to meet primary endpoints or show inferior safety profiles, severely dampening future revenue estimates. Aggressive implementation of the U.S. Inflation Reduction Act (IRA) and China's Value-Based Purchasing (VBP) exerts downward pressure on pricing for top-selling drugs like Tagrisso and Farxiga. Geopolitical deterioration leads to a forced decoupling or severe sanctions impacting the China business unit. Higher-for-longer global interest rates compress valuations for high-multiple pharma stocks, causing a de-rating of the stock back to historical lows.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus